drugset / Trial / NCT01838902

Primaquine's Gametocytocidal Efficacy in Malaria Asymptomatic Carriers

NCT01838902

Phase 3 Completed 467 enrolled London School of Hygiene and Tropical Medicine
RandomizedParallel-groupOpen-labelTreatment

Summary

In this study, the investigators are interested to know if lower doses of Primaquine together with dihydroartemisinin-piperaquine can produce a similar effect of clearing both sexual and asexual parasites in asymptomatic carriers compared to the recommended dose of primaquine but with a decreased risk of haemolysis. Children (\> 1 year) and adults with normal Glucose-6-phosphate dehydrogenase enzyme levels but with asexual Plasmodium falciparum parasites on the day of screening will be invited to take part in this study.

Timeline

Start
2013-08
Primary completion
2015-02
Completion
2015-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Primaquine Small molecule 0.2 mg/kg
Subject Primaquine Small molecule 0.4 mg/kg
Subject Primaquine Small molecule 0.75 mg/kg
Background ARTENIMOL Small molecule
Background piperaquine Small molecule

Indications